Barbra Sasu, PhD - 2021 World Medical Innovation Forum
Boston
May 2–4, 2022
Barbra Sasu
This speaker appears at this event:

This speaker appears in these events:

Barbra Sasu, PhD

CSO, Allogene

Barbra Sasu, PhD, is the Chief Scientific Officer of Allogene. Barbra joined Allogene as Chief Scientific Officer in April 2018 when the company acquired the allogeneic cell therapy assets from Pfizer. Barbra received a PhD from the Paterson Institute for Cancer Research in Manchester, UK, in the laboratory of T. Michael Dexter, FRS. She conducted postdoctoral research at Harvard Medical School in the laboratory of T. Keith Blackwell, MD, PhD Barbra joined Amgen in 2001 to work on normal and malignant hematology initially and later expanded her focus to include immune-oncology with an emphasis on T cell redirective therapies, specifically BiTE molecules. In 2013, she joined Pfizer to become involved with large molecule immuno-oncology including the Pfizer T cell redirection programs and led diligence to look for a CAR T collaboration partner. This collaboration search resulted in the Cellectis partnership in 2014 and the collaboration with Servier for clinical execution of UCART19 and other preclinical assets.

the Future of Medicine and AI

May 11–13, 2020 | Boston, MA